These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21188808)

  • 1. Entacapone: prostate cancer?
    Prescrire Int; 2010 Oct; 19(109):217. PubMed ID: 21188808
    [No Abstract]   [Full Text] [Related]  

  • 2. Entacapone and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study.
    Major JM; Dong D; Cunningham F; By K; Hur K; Shih DC; Jiang R; Podskalny GD; Wei X; Pinheiro S; Bird ST; Keeton S; Graham DJ
    Parkinsonism Relat Disord; 2018 Aug; 53():46-52. PubMed ID: 29759929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Entocapone-related lymphocytic colitis].
    Maroy B
    Gastroenterol Clin Biol; 2008; 32(8-9):695-7. PubMed ID: 18436401
    [No Abstract]   [Full Text] [Related]  

  • 4. Bullous skin eruption associated with entacapone.
    Foti C; Cassano N; De Mari M; Sorino M; Vena GA
    Int J Dermatol; 2004 Jun; 43(6):471-2. PubMed ID: 15186236
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous dopaminergic therapy in Parkinson disease: time to stride back?
    Stoessl AJ
    Ann Neurol; 2010 Jul; 68(1):3-5. PubMed ID: 20583222
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
    Manca D; Cossu G; Murgia D; Molari A; Ferrigno P; Marcia E; Melis M
    Mov Disord; 2009 Nov; 24(15):2293-4. PubMed ID: 19795477
    [No Abstract]   [Full Text] [Related]  

  • 7. [78-year-old patient with urine discoloration].
    Krause O; Griebel LF; Heck J
    Dtsch Med Wochenschr; 2022 Jan; 147(1-02):15-16. PubMed ID: 34963169
    [No Abstract]   [Full Text] [Related]  

  • 8. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
    Nyholm D; Askmark H; Aquilonius SM
    Ann Neurol; 2011 Feb; 69(2):424; author reply 425. PubMed ID: 21387388
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe hypertension following ephedrine administration in a patient receiving entacapone.
    Renfrew C; Dickson R; Schwab C
    Anesthesiology; 2000 Dec; 93(6):1562. PubMed ID: 11149468
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neuromuscular disorders due to adverse effects of antiparkinson agents].
    Hattori N
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1614-20. PubMed ID: 17802710
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
    Destée A; Rérat K; Bourdeix I
    Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMT inhibition with entacapone in the treatment of Parkinson's disease.
    Rinne UK; Gordin A; Teräväinen HT
    Adv Neurol; 1999; 80():491-4. PubMed ID: 10410761
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMT inhibition and safety.
    Martignoni E; Blandini F; Pacchetti C; Nappi G
    Funct Neurol; 2001; 16(4 Suppl):135-40. PubMed ID: 11996508
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
    Kupsch A; Trottenberg T; Bremen D
    Curr Med Res Opin; 2004 Jan; 20(1):115-20. PubMed ID: 14741081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
    Silver DE
    Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.